Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04243837 · ClinicalTrials.gov registry record · Phase 2
LYT-100 in Patients With BCRL
A Phase 2 study, sponsored by PureTech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT04243837: Clinical Trial Phase 2 study, sponsored by PureTech.
NCT04243837 is a Phase 2 study that was terminated before completion, run by PureTech. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04243837, a Phase 2 study, was terminated before completion, sponsored by PureTech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a trial of up to 6-months duration for safety, tolerability, clinical efficacy assessments, PK and biomarkers analysis in breast carcinoma patients with secondary lymphoedema
Primary Outcome
Evaluate the safety and tolerability of LYT-100 as measured by TEAEs
Interventions
- DRUG LYT-100 BCRL
- DRUG Placebo BCRL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2022-09-09 |
| Phase | Phase 2 |
Why NCT04243837 stopped before completion
NCT04243837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which LYT-100 BCRL is the first listed.
NCT04243837 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04243837 about?
NCT04243837 is a clinical study titled "LYT-100 in Patients With BCRL". This is a trial of up to 6-months duration for safety, tolerability, clinical efficacy assessments, PK and biomarkers analysis in breast carcinoma patients with secondary lymphoedema
What is the current status of trial NCT04243837?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2020-03-01. Estimated completion is 2022-09-09.
What interventions are being tested in trial NCT04243837?
The interventions under investigation include: LYT-100 BCRL (DRUG), Placebo BCRL (DRUG).
Who is sponsoring clinical trial NCT04243837?
This trial is sponsored by PureTech, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04243837's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI